MX2009006235A - Composiciones farmaceuticas y sus metodos de uso. - Google Patents

Composiciones farmaceuticas y sus metodos de uso.

Info

Publication number
MX2009006235A
MX2009006235A MX2009006235A MX2009006235A MX2009006235A MX 2009006235 A MX2009006235 A MX 2009006235A MX 2009006235 A MX2009006235 A MX 2009006235A MX 2009006235 A MX2009006235 A MX 2009006235A MX 2009006235 A MX2009006235 A MX 2009006235A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical compositions
manufacture
composition
same
Prior art date
Application number
MX2009006235A
Other languages
English (en)
Inventor
Jianguo Ji
Michael R Schrimpf
Tao Li
Kevin B Sippy
David J Anderson
Murali Gopalakrishnan
John Malysz
Chih-Hung Lee
Marie P Honore
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009006235A publication Critical patent/MX2009006235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)

Abstract

La invención se refiere a una composición que comprende un ligando de un receptor nicotínico neuronal y un modulador alostérico positivo de a4ß2, un método para usarla y un artículo de fabricación relacionado.
MX2009006235A 2006-12-12 2007-12-12 Composiciones farmaceuticas y sus metodos de uso. MX2009006235A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87460906P 2006-12-12 2006-12-12
US99976107P 2007-04-12 2007-04-12
US11/953,625 US20080167286A1 (en) 2006-12-12 2007-12-10 Pharmaceutical compositions and their methods of use
PCT/US2007/087090 WO2008073942A2 (en) 2006-12-12 2007-12-12 Pharmaceutical compositions and their methods of use

Publications (1)

Publication Number Publication Date
MX2009006235A true MX2009006235A (es) 2009-06-22

Family

ID=39427547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006235A MX2009006235A (es) 2006-12-12 2007-12-12 Composiciones farmaceuticas y sus metodos de uso.

Country Status (16)

Country Link
US (3) US20080167286A1 (es)
EP (3) EP2974727A1 (es)
JP (1) JP2010512419A (es)
KR (1) KR20090098884A (es)
AU (1) AU2007333129A1 (es)
BR (1) BRPI0720124A2 (es)
CA (1) CA2671683A1 (es)
CO (1) CO6210820A2 (es)
CR (1) CR10873A (es)
DO (1) DOP2009000137A (es)
EC (1) ECSP099495A (es)
ES (2) ES2389116T3 (es)
MX (1) MX2009006235A (es)
NO (1) NO20092584L (es)
TW (1) TW200901995A (es)
WO (1) WO2008073942A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777663A (en) * 1986-08-08 1988-10-11 Corning Glass Works Data rate limiter for optical transmission system
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
IL169855A (en) * 2005-07-25 2014-05-28 Elta Systems Ltd A system and method for locating a receiver location
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7834039B2 (en) 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
SI2481410T1 (sl) 2007-01-31 2017-01-31 Bial - Portela & Ca., S.A. Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom
AU2008293542B9 (en) * 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
EP2231643B1 (de) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
ES2455197T3 (es) * 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
CN102089297A (zh) * 2008-06-06 2011-06-08 雅培制药有限公司 新的1,2,4-噁二唑化合物和其使用方法
AU2009304596A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1P receptors modulators
CA2740484C (en) 2008-10-17 2021-09-21 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
WO2010080757A2 (en) * 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
DK2413912T3 (da) 2009-04-01 2019-06-17 Bial Portela & Ca Sa Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
US9040568B2 (en) * 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
EP2488030B1 (de) 2009-10-12 2015-01-07 Bayer CropScience AG 1-(pyrid-3-yl)-pyrazole und 1-(pyrimid-5-yl)-pyrazole als schädlingsbekämpfungsmittel
US8461171B2 (en) * 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
KR101551481B1 (ko) * 2011-09-19 2015-09-08 수벤 라이프 사이언시스 리미티드 ５－ηｔ４ 수용체 리간드인 헤테로아릴 화합물
EP2769216B1 (en) * 2011-10-20 2017-01-04 Chromocell Corporation Assays for identifying compounds that modulate bitter taste
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
SG11201508572UA (en) 2013-04-24 2015-11-27 Chromocell Corp Assays for identifying compounds that modulate bitter taste
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
KR102096420B1 (ko) * 2015-03-31 2020-04-02 몬산토 테크놀로지 엘엘씨 2-싸이오펜카보닐 클로라이드의 제조 방법
US10745376B2 (en) 2016-03-24 2020-08-18 Monsanto Technology Llc Processes for the preparation of heteroaryl carboxylic acids
US11439623B2 (en) * 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2950707A (en) 1959-10-13 1960-08-30 Butler Frank David Combined liquid fuel and excess air metering and distributing, combined liquid fuel and excess air atomizing and injecting, internal combustion engine
US3964896A (en) * 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
CH623971B5 (de) * 1976-06-04 1982-01-15 Hoechst Ag Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller.
AU3171493A (en) 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5914328A (en) * 1992-10-09 1999-06-22 Abbott Laboratories Heterocyclic ether compounds useful in controlling neurotransmitter release
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
ES2221234T3 (es) 1997-12-19 2004-12-16 Abbott Laboratories Compuestos de eter y tioeter heterociclicos utilizados en la regulacion de la transmision sinaptica quimica.
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
AU4230799A (en) 1998-06-16 2000-01-05 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6207863B1 (en) 1998-08-11 2001-03-27 Rohm And Haas Company Synthesis of haloformimine compounds
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US6833370B1 (en) * 1999-05-21 2004-12-21 Abbott Laboratories Heterocycle substituted aminoazacycles useful as central nervous system agents
DE60011895T2 (de) 1999-05-21 2005-08-04 Abbott Laboratories, Abbott Park Heterocyclische subtituierte aminoazacyclische verbindungen mit zentraler nervensystemwirkung
AU5326100A (en) 1999-06-07 2000-12-28 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) * 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP2001302643A (ja) 2000-04-21 2001-10-31 Suntory Ltd 環状アミジン化合物
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
ATE375340T1 (de) 2001-02-21 2007-10-15 Nps Pharma Inc Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten
MXPA03011196A (es) * 2001-06-08 2004-10-28 Cytovia Inc 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos.
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
MXPA04004464A (es) * 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
US7135484B2 (en) * 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
BR0313662A (pt) 2002-08-20 2005-06-14 Procter & Gamble Método para produção de composições detergentes em gel lìquido contendo solvente anidro para lavagem de pratos em lavadora automática
SI3889142T1 (sl) * 2003-04-11 2022-10-28 Ptc Therapeutics, Inc. Spojine 1,2,4-oksadiazol benzojske kisline in njihova uporaba za zatiranje nesmiselne ter zdravljenje bolezni
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7807696B2 (en) * 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
DE102004033834A1 (de) * 2004-07-13 2006-02-02 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel
AU2005275182A1 (en) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
EP1812001A2 (en) * 2004-10-21 2007-08-01 The Trustees Of Columbia University In The City Of New York Nicotinic-opioid synergy for analgesia
US8378109B2 (en) 2004-12-07 2013-02-19 The Regents Of The University Of California Labeled ALPHA4BETA2 ligands and methods therefor
JP2008525524A (ja) 2004-12-28 2008-07-17 アストラゼネカ・アクチエボラーグ アリールスルホンアミドモジュレーター
CA2593044A1 (en) 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
JP5125501B2 (ja) * 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物
US7019503B1 (en) 2005-02-07 2006-03-28 Raytheon Company Active power filter with input voltage feedforward, output load feedforward, and output voltage feedforward
US20080261999A1 (en) * 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
DE102005014904A1 (de) * 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
EP1861392A2 (de) * 2005-03-24 2007-12-05 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
ATE477253T1 (de) * 2005-04-26 2010-08-15 Neurosearch As Neuartige oxadiazol-derivate und deren medizinische verwendung
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ES2422275T3 (es) 2006-12-30 2013-09-10 Abbott Gmbh & Co Kg Derivado del oxindol sustituido y su uso como un modulador del receptor de la vasopresina
DK2114921T3 (da) 2006-12-30 2013-03-25 Abbott Gmbh & Co Kg Substitueret oxindolderivat og dets anvendelse som en vasopressin­receptorligand
WO2008080971A1 (en) 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Substituted oxindole derivative and its use as a vasopressin receptor ligand
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
EP2231643B1 (de) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
BRPI0820668A2 (pt) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
ES2455197T3 (es) 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
CN102089297A (zh) 2008-06-06 2011-06-08 雅培制药有限公司 新的1,2,4-噁二唑化合物和其使用方法
US9040568B2 (en) * 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
CN101730041A (zh) 2009-06-26 2010-06-09 中兴通讯股份有限公司 一种基于用户当前所在时区的策略和计费控制方法及系统
EP2571882A1 (en) 2010-05-21 2013-03-27 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors

Also Published As

Publication number Publication date
KR20090098884A (ko) 2009-09-17
EP2226074B1 (en) 2015-11-04
CR10873A (es) 2009-07-23
US20110190314A1 (en) 2011-08-04
EP2101763A2 (en) 2009-09-23
ES2389116T3 (es) 2012-10-23
BRPI0720124A2 (pt) 2014-03-04
WO2008073942A3 (en) 2008-12-04
ECSP099495A (es) 2009-08-28
US20160022658A1 (en) 2016-01-28
AU2007333129A1 (en) 2008-06-19
JP2010512419A (ja) 2010-04-22
EP2101763B1 (en) 2012-07-18
WO2008073942A2 (en) 2008-06-19
EP2226074A3 (en) 2011-03-09
EP2226074A2 (en) 2010-09-08
NO20092584L (no) 2009-09-14
EP2974727A1 (en) 2016-01-20
CA2671683A1 (en) 2008-06-19
DOP2009000137A (es) 2009-06-30
CO6210820A2 (es) 2010-10-20
US20080167286A1 (en) 2008-07-10
TW200901995A (en) 2009-01-16
ES2558054T3 (es) 2016-02-01
US9186407B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
MX2009006235A (es) Composiciones farmaceuticas y sus metodos de uso.
FR2883179B1 (fr) Comprime enrobe
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2010008714A (es) Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
HK1139864A1 (en) Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
EP2024272A4 (en) AMID DERIVATIVES AS ION CHANNEL NIGANDS, AND PHARMACEUTICAL COMPOSITIONS AND USER METHOD THEREFOR
MY161550A (en) Extended release oral acetaminophen/tramadol dosage form
PL1902706T3 (pl) Trwałe w roztworze kompozycje farmaceutyczne tetracyklin, sposób ich otrzymywania i ich zastosowania
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
ZA201001018B (en) Polyamide and emollient compositions, products made therefrom, and methods of making and using such compositions and products
WO2009145996A3 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
SI2036892T1 (sl) Derivati tetrahidro h benzazepinov postopek za njihovo pripravo in farmacevtski sestavkiki jih vsebujejo
WO2007084535A3 (en) Neuronal nicotinic receptor ligands and their use
SI2030612T1 (sl) Farmacevtski sestavek za zdravljenje opeklin in postopek za njegovo izdelavo
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
HK1155943A1 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
HK1126190A1 (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
WO2008148747A8 (en) Pdz domain modulators
GB0620619D0 (en) Novel compounds
PL383412A1 (pl) Nowe peptydowe kompleksy platyny, sposób ich otrzymywania, kompozycja farmaceutyczna i zastosowanie
SI2139485T1 (sl) Postopki dajanja tetrahidrobiopterina, povezani sestavki in postopki merjenja
UA27344U (en) Use of pollentar pharmaceutical composition as cerebroprotective agent
TN2010000354A1 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
EP2117313A4 (en) PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM
ZA201000657B (en) Pharmaceutical compositions and process for making them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal